Bedaquiline price threshold analysisa | |||||||
---|---|---|---|---|---|---|---|
 | Estonia | Russia | South Africa | Peru | China | Philippines | India |
WHO CE thresholds (1x GDP-3x GDP), US$ (Cost per DALY averted) | 16,844 – 50,532 | 14,037 – 42,111 | 7,352 – 22,056 | 6,796 – 20,388 | 6,091 - 18,273 | 2,587 – 7,761 | 1,503 – 4,509 |
Cost-effective price range, US$b | 91,984 – 203,492 | 73,909 – 156,427 | 29,151 – 72,701 | 36,421 – 92,953 | 23,904 – 62,593 | 8,567 – 22,992 | 6,996 – 20,323 |
Bedaquiline plus BR vs. BR alone price range for cost-effectiveness analysis | |||||||
 Half lowest range price, US$ | 45,992 | 36,955 | 14,576 | 18,211 | 11,952 | 4,284 | 3,498 |
 Lowest range price, US$ | 91,984 | 73,909 | 29,151 | 36,421 | 23,904 | 8,567 | 6,996 |
 Mid-range price, US$ | 147,738 | 115,168 | 50,926 | 64,687 | 43,428 | 15,285 | 13,660 |
 Highest-range price, US$ | 203,492 | 156,427 | 72,701 | 92,953 | 62,593 | 22,002 | 20,323 |
 Double highest range price, US$ | 406,984 | 312,854 | 145,402 | 185,906 | 125,186 | 44,004 | 40,646 |